Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept.

摘要: Purpose: Conbercept (KH902), a novel recombinant, soluble vascular endothelial growth factor (VEGF) receptor–IgG fusion protein, has been developed as new drug for ocular neovascularization and macular edema. The present study aims to clarify the changes in conbercept levels, VEGF, intraocular pressure (IOP) after intravitreal injection of into diabetic mouse eyes. Methods: Five-week-old C57BL/6 mice were injected with streptozotocin induce diabetes. Total VEGF levels eyes detected using an ELISA kit at −2 h, 1 d, 4 8 16 28 34 d control mice. IOP was measured noninvasive TonoLab tonometer 7 injection. Results: concentration treated increased immediately remained high (29.77±27.19 ng/ml, 20.28±28.85 42.43±36.51 ng/ml days 1, 2, 4, respectively). untreated fellow from day 2 level about 1% that concentrations both decreased significantly h when compared baseline before (645.91±86.47 pg/ ml versus 296.10±76.11 pg/ml 860.50±201.47 377.69±70.72 pg/ml, reached its peak 24 then thereafter. At injection, difference between received PBS injections not significant (p>0.05). Conclusions: total elevated conbercept. Increased likely reflect sequestered by These data could be helpful understand ing metabolism anti-VEGF drugs eye determining protocol multiple patients.